Member Info for LlamaFarmer

Followed by ...

The Annual General Meeting will take place at 12.00 noon on 27 June 2025 at the Company's registered office being, 25 Eccleston Place, London SW1W 9NF.

Https://www.proactiveinvestors.co.uk/register/event_details/458

Solvonis ...

V.s.

And that value sof almost 4p a share is only for 001 and 002.

Professor Nutt has given then 014 plus,a whole library of Central Nervous System data.

ChasBrown

You need to email info@lse.co.uk.

The BOD are showing some class here.

Large dilutive placing, not to pay Directors bonuses and wage increases but to bring to UK shores and fund the testing of SVNS product line, all the same a lot of dilution until you understand the story!

They know that to build a stable share price to launch the businesses growth from they need to turn this stock over so they are utilising gentle news flow.

Telling us what we already know or can find out, nothing ground breaking - not yet.

In the background things moving on nicely, fully funded.

End of this month

AGM

Proactive Interview.

Bline - what you saw was the holding for William Potts https://www.lse.co.uk/rns/SVNS/holdings-in-company-g4ch4qvi2hrij41.html 610m

Resulting situation on the date on which threshold was crossed or reached 10.33 Nil 10.33 610,461,538

RNS 30th May 2025

https://www.lse.co.uk/rns/SVNS/total-voting-rights-sbiyhn3ctp750mp.html

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of addiction and mental health disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 5,908,770,690 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 5,908,770,690.

Tricky, she links to Anthony Tennyson' comment re Ozempic now being worth Billions and SVNS being new to the U.K.

Crome is currently a consultant for Novo Nordisk, the maker of Ozempic, and has previously led a UK government-backed Covid-19 treatments programme.

Chair Dennis Purcell said: "Her extensive experience in drug development, regulatory affairs, and commercial strategy, combined with her governance expertise, will be invaluable as Solvonis continues to advance its innovative therapies in the mental health and addiction spaces."

Tbh there's no need to research this it's an obvious buy and hold.

Https://firstwordpharma.com/story/5971486

Read that through a few times, then remind yourself it does NOT include

SVN 001

SVN 002

SVN 014

Unsure what the correct value is, pretty sure its not a market cap of £13m

Times that by 10 or by 50?

Who knows? this is Pharma, the land of crazy valuations and a company dealing with unmet psychological needs of the masses.

Looking at one of the examples Anthony Tennyson provided to Zak Muir.

Why is Ozempic so expensive?

AI Overview

Ozempic is expensive primarily due to Novo Nordisk's patent on semaglutide, the active ingredient, and the high cost of research and development. Additionally, the drugmaker sets high prices to recoup these costs and generate profit for shareholders. The high cost is further exacerbated in the US, where the company is accused of price gouging and treating the US market as a "cash cow".

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year

Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that comfortably beat Wall Street expectations. But the drugmaker said it expected sales growth to slow in 2025, as competition increases.

Wegovy was approved for weight loss in 2021.

In 2021, Ozempic generated DKK 33.71 billion (approximately $5.36 billion USD) in sales for Novo Nordisk

Like for like that would be just under a US $pershare or 74p

That was in 2021, in 2024 it spiked at $40.6B almost $7 per share.

This guy is on fire with his tweets, great info very well presented in a clear and easy to understand format.

https://x.com/SerialInvestor8/status/1933897485639975406

UK SVN 001 test has slightly higher doseage of the synthesised/Patented Ketamine than the USA F.D.A. trial.

When they design these novel candidates they have a few chemical options to pursue and choose the methosmd that gives the best results and causes the least harm.

Prof Nutt explained in the RNS last week they are going to run his library of products for the Central Nervous System through AI to provide a cause and effect type knowledge database.

He has also started campaigning for the Govt to let them test other psychedelics.

Foots on the accelerator.

Https://psychiatryonline.org/doi/10.1176/appi.ajp.2021.21030277

three ketamine infusions were administered weekly, as this has been shown to be effective in earlier research (13). We furthermore aimed to pilot ketamine combined with mindfulness-based relapse prevention therapy (henceforth “therapy”) compared with ketamine plus alcohol education (as a therapy control). This type of psychological therapy was chosen because it has been shown to be effective, and the ketamine experience can be considered to potentially promote engagement in mindfulness practice by giving experiential insights. Thus, in this phase 2 clinical trial, we compared four treatment conditions: 1) ketamine (active) and therapy (active), 2) ketamine (active) and alcohol education (control), 3) saline (control) and therapy (active), and 4) saline (control) and alcohol education (control). We hypothesized that ketamine plus therapy (active plus active) would be most effective in sustaining abstinence and that the lowest abstinence rates would be in the placebo plus education group (control plus control).

Thin Film Ketamine - IP owned and patents pending by SVNS, designed by world renowned Professor David Nutt!

Alcohol Education system - copyrighted by Awakn

UK NHS NIHC Doseage - Phase 3

USA FDA Doseage - Phase 2

I might have upset Mr AVCT :)

Can't even copy a link correctly 🤦

Andy, I added as well this afternoon.

Looking leaky?

Jeez, what have we bought?

This was a year ago, its got even bigger since then.

https://www.semafor.com › article › ozempic-maker-no...

31 Jan 2024 — Ozempic maker passes $500 billion in market value ; Doctors worry about Ozempic's reputation as 'vanity' drug instead of diabetes treatment.

Https://zakstraderscafe.com/interview-solvonis-therapeutics/11936/

Zak:Why is it only £7.68m and not billions, it can achieve billions can't it?

Anthony: Well we've just brought it over here when we purchased Awakn in Canada so it's new, like Ozempic was new, but that was using the diabetic drug, that had been in use for years.

This now is new and treats an equally significant problem area.

Zak: so it really can be worth billions then!

What a lovely interview.

Couldn't be bothered to be overly drawn on the financial side to the business, wanted to drum the message home about what they have got.

They know that big money follows Novel combination treatments for large scale problem areas so pointless explaining it, Pharma are either hundreds of millions or Billions.

What is important is that their projects work, they own the IP and then to link it to Ozempic was a masterstroke of delivery.

BUY,HOLD,WAIT

Yep, two weeks churn till it gets exciting again at AGM, never know the price might dip as traders leave, can add to positions?